SYDNEY, Sept. 3, 2014 /PRNewswire/ -- Novogen Ltd. (ASX:
NRT, NASDAQ: NVGN) today announced that Graham Kelly PhD, CEO, will
present at the Rodman & Renshaw 16th Annual Healthcare
Conference on Wednesday, September
10th in New York. Dr. Kelly will provide an
overview of the two Novogen first-in-class drug technology
platforms in the field of oncology. His presentation will
take place at the New York Palace Hotel and will begin at
10:25am.
About Novogen Limited
Novogen is a public, Australian drug-development company whose
shares trade on both the Australian Securities Exchange ('NRT') and
NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT-based joint venture company,
CanTx Inc, with Yale University.
Novogen has two main drug technology platforms:
super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP
compounds have been created to kill the full range of cells within
a tumor, but particularly the cancer stem cells. The ATM compounds
target the microfilament component of the cancer cell and when used
in conjunction with standard anti-microtubular drugs, result in
comprehensive and fatal destruction of the cancer cell's
cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites,
prostate cancer, neural cancers (glioblastoma, neuroblastoma) and
melanoma are the key clinical indications being pursued, with the
ultimate objective of employing both technologies as a unified
approach to first-line therapy.
Further information is available on the Company's
website, www.novogen.com.
For more information please contact:
Corporate
Contact
|
Media
enquiries
|
Executive Chairman
& CEO Novogen
Group Graham.Kelly@novogen.com +61 (0) 2 9472 4100
|
In the
USA:
|
Lazar
Partners Novogen@lazarpartners.com +1
212-867-1762
|
|
|
Investors
enquiries
|
In
Australia:
|
In the
USA:
Lazar
Partners
Novogen@lazarpartners.com
+1
212-867-1762
|
Dr. Douglas
Pretsell
Instinctif
Partners
+61 (0) 3 9657
0706
|
|
In
ROW:
|
|
Sue
Charles
Instinctif
Partners
+44 (0) 20 7457
2020
|
Logo -
http://photos.prnewswire.com/prnh/20131220/NY36990LOGO
SOURCE Novogen Ltd.